Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products

Core Insights - Femasys Inc. has announced a strategic distribution partnership with OR Consulting to launch its product portfolio in Switzerland, which includes FemBloc Permanent Birth Control and FemaSeed Intratubal Insemination, as part of its European expansion strategy [1][2] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of therapeutic and diagnostic products [3] - The company's fertility portfolio includes FemaSeed, which is over twice as effective as traditional IUI, and FemVue, a companion diagnostic for fallopian tube assessment [3] Product Details - FemBloc is the first non-surgical, in-office alternative to surgical sterilization, receiving full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025 [4] - The FemChec diagnostic product provides an ultrasound-based test to confirm procedural success, demonstrating compelling effectiveness and high satisfaction among patients and practitioners [4] Market Strategy - The partnership with OR Consulting is aimed at strengthening Femasys' European commercial platform and expanding access to its innovative technologies through experienced regional partners [2] - The ongoing launches in Spain and France, along with the entry into Switzerland, reflect the company's disciplined approach to building a multi-country footprint [2]